gptkbp:instanceOf
|
gptkb:Company
|
gptkbp:activeDuring
|
various biomarkers
|
gptkbp:availability
|
prescription only
|
gptkbp:clinicalTrials
|
completed
Phase III
published in journals
follow guidelines
proven effective
improved diagnosis
monitoring health conditions
recommended by health authorities
|
gptkbp:collaborations
|
various research institutions
|
gptkbp:community_service
|
offered
|
gptkbp:communityOutreach
|
conducted regularly
|
gptkbp:contraindication
|
rare
none reported
|
gptkbp:customerFeedback
|
considered in improvements
|
gptkbp:date
|
FDA_approved
|
gptkbp:distributionChannels
|
pharmacies
|
gptkbp:drugInterdiction
|
minimal
|
gptkbp:educational_programs
|
available online
|
gptkbp:formulation
|
liquid
|
gptkbp:hasCompetitors
|
other diagnostic tests
|
gptkbp:hasPopulation
|
diverse demographics
|
gptkbp:healthcare
|
available
monitored
provided by healthcare professionals
|
https://www.w3.org/2000/01/rdf-schema#label
|
OPKO 1200
|
gptkbp:insuranceAccepted
|
varies by plan
|
gptkbp:is_monitored_by
|
regular check-ups
|
gptkbp:launchDate
|
2015
|
gptkbp:manufacturer
|
gptkb:OPKO_Health,_Inc.
|
gptkbp:marketedAs
|
gptkb:United_States
|
gptkbp:marketingStrategy
|
direct-to-consumer
|
gptkbp:packaging
|
vials
|
gptkbp:patentAssignee
|
gptkb:OPKO_Health,_Inc.
|
gptkbp:priceRange
|
varies by location
|
gptkbp:productionCompany
|
marketed
|
gptkbp:publications
|
peer-reviewed articles
|
gptkbp:regulatoryBody
|
gptkb:FDA
|
gptkbp:regulatoryCompliance
|
ensured
|
gptkbp:research
|
private and public sources
|
gptkbp:research_areas
|
oncology
|
gptkbp:researchInterest
|
ongoing
with universities
|
gptkbp:route
|
injection
|
gptkbp:safetyFeatures
|
ongoing
generally safe
|
gptkbp:shelfLife
|
24 months
|
gptkbp:sideEffect
|
mild reactions
|
gptkbp:storage
|
room temperature
|
gptkbp:supplyChain
|
managed_by_OPKO_Health.
|
gptkbp:targets
|
adults
|
gptkbp:type
|
diagnostic test
|
gptkbp:usedFor
|
detecting diseases
|
gptkbp:userReviews
|
generally positive
|